MBHB Partner Kevin Noonan on the Evolving Landscape of Vaccine Patent Litigation

In Vaccine Insights, MBHB Partner Kevin Noonan examines the shift toward renewed patent litigation following the COVID-19 pandemic. He highlights a series of disputes involving mRNA vaccine technologies and considers how these developments may shape companies’ strategies for protecting innovation in the life sciences sector. Read the article.